Treatment prediction for precision oncology
Biomarkers are useful for patient stratification but seldom predict individual treatment accurately, nor are they available for all therapies—particularly chemotherapy.
Ex vivo drug-sensitivity assays using patient material show technical maturity and the promise to predict treatment response, but their development and clinical implementation remain challenging.
The current lack of standardized frameworks and defined minimal requirements for treatment prediction assays hampers their clinical implementation.
Proper and timely consideration of clinical feasibility and utility is essential to increase the chance of positive value assessments and implementation.
https://www.cell.com/trends/cancer/fulltext/S2405-8033(26)00219-0
